Publication: Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future
Issued Date
2018-01-01
Resource Type
ISSN
16878345
16878337
16878337
Other identifier(s)
2-s2.0-85058840621
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Endocrinology. Vol.2018, (2018)
Suggested Citation
Nattakarn Suwansaksri, Lukana Preechasuk, Tada Kunavisarut Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future. International Journal of Endocrinology. Vol.2018, (2018). doi:10.1155/2018/5794054 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45308
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future
Other Contributor(s)
Abstract
© 2018 Nattakarn Suwansaksri et al. Hyperthyroidism is a common endocrine disease. Although thionamide antithyroid drugs are the cornerstone of hyperthyroidism treatment, some patients cannot tolerate this drug class because of its serious side effects including agranulocytosis, hepatotoxicity, and vasculitis. Therefore, nonthionamide antithyroid drugs (NTADs) still have an important role in controlling hyperthyroidism in clinical practice. Furthermore, some situations such as thyroid storm or preoperative preparation require a rapid decrease in thyroid hormone by combination treatment with multiple classes of antithyroid drugs. NTADs include iodine-containing compounds, lithium carbonate, perchlorate, glucocorticoid, and cholestyramine. In this narrative review, we summarize the mechanisms of action, indications, dosages, and side effects of currently used NTADs for the treatment of hyperthyroidism. In addition, we also describe the state-of-the-art in future drugs under development including rituximab, small-molecule ligands (SMLs), and monoclonal antibodies with a thyroid-stimulating hormone receptor (TSHR) antagonist effect.